Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 28, Issue 5, Pages 267-272

Progression Model Tissue Microarray (TMA) for the Study of Uterine Carcinomas

Mohammad Arafa,1 Jacques Boniver,2 and Philippe Delvenne2

1Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
2Department of Anatomic Pathology and Cytology, GIGA-Cancer, University of Liege, Liege, Belgium

Received 25 June 2010; Accepted 25 June 2010

Copyright © 2010 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cervical and endometrial uterine carcinomas are heterogeneous groups of cancers, which are preceded by preneoplastic lesions. More accurate tools are needed to improve the diagnosis and to define markers which may be relevant for the diagnosis, prediction of disease progression and therapeutic response.

High throughput technologies for testing and validating molecular targets in cancer lesions and in their precursors are presently available. Among them, the tissue microarray (TMA) presents the advantage of a morphological control of the analyzed tissue fragment. In this article, we review the different aspects of the TMA technology with a special consideration to a uterine carcinogenesis model.